<DOC>
	<DOCNO>NCT00430898</DOCNO>
	<brief_summary>The purpose study assess safety , effectiveness pharmacokinetics two level intravenous basiliximab ulcerative colitis , compare placebo .</brief_summary>
	<brief_title>Basiliximab Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>In addition others , Men woman age 1875 Diagnosis ulcerative colitis confirm screen endoscopy . Extent disease must involve least left colon Moderate severe disease ( Mayo Score 612 ) . Systemic feature tachycardia , fever , and/or significant anemia present . Inadequate response despite treatment prednisone 40 50 mg/day ( oral steroid equivalent dose ) orally minimum 14 day immediately precede study entry In addition protocoldefined condition , Pregnancy Stool study show presence ovum parasite , significant bacterial pathogen , C. difficile toxin Colitis indeterminate , suggestive Crohn 's disease , isolated rectum , base endoscopic and/or biopsy finding Severely ill patient evidence protocoldefined systemic criterion Chest radiograph abnormality consistent infectious process History colonic dysplasia HIV infection Known viral Hepatitis B C infection History exposure tuberculosis within 6 month study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>ulcerative colitis basiliximab</keyword>
</DOC>